FAM20B

Across TCGA pan-cancer cohorts, FAM20B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM20B data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM20B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM20B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where FAM20B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	13	view →
GBM	OS	Quartile	All	0.536	0.256	.009	7	view →
PDAC	DFS	Quartile	All	0.326	0.522	.035	2	view →
LSCC	OS	Tertile	All	0.839	0.926	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM20B–CCRCC (OS)

Open the CCRCC breakdown →